The Serum Institute of India's plans to raise as much as $12 billion by offering equity in Asia's largest vaccinemaker are on hold, for now, as global market volatility stands in the way of valuation.
India's Pune-based Serum Institute is seeking in-country fast-track approval for a biologic drug candidate to treat all four strains of dengue, the Times of India reported, with the news coming amid speculation over an equity offering by the company and a massive virus outbreak in India.
Researchers at the University of California, Berkeley, have identified a viral protein that causes fluid loss and shock that indicate severe and potentially fatal dengue infections.
With its largest ever investment in a vaccine at stake, Sanofi is in the midst of rolling out the dengue fever vaccine it's worked on for 20 years at a cost of $1.5 billion. But through the launch, Sanofi hopes to recoup all of that expense--plus more.
After the company's largest investment ever in the development of a vaccine, Sanofi Pasteur's dengue vaccine launch is ready for this year, and it'll be closely watched as the group introduces the jab in a manner reversed from traditional launches.
Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.
So far, Sanofi's dengue candidate, the furthest along in the clinic, has struggled to ward off all four dengue viruses. But now, researchers have discovered new antibodies that could lead to a vaccine that does just that.
Analysts have said Sanofi's dengue vaccine, once approved, could rake in €1 billion, or $1.31 billion, a year. According to a report from Brandeis University, the number of dengue cases in the India is almost 300 times higher than government figures.
Expanded results from Sanofi's Latin American Phase III dengue vaccine trial are here, and the pharma giant says they confirm the high efficacy against severe dengue and the reduction in hospitalization the jab posted in its first Phase III study. And with these in tow, the company says it could have the vaccine to market by the second half of next year.
Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.